FABOMOTIZOLE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C15H21N3O2S
Molecular Weight	307.411
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC1=CC2=C(NC(SCCN3CCOCC3)=N2)C=C1

InChI

InChIKey=WWNUCVSRRUDYPP-UHFFFAOYSA-N

InChI=1S/C15H21N3O2S/c1-2-20-12-3-4-13-14(11-12)17-15(16-13)21-10-7-18-5-8-19-9-6-18/h3-4,11H,2,5-10H2,1H3,(H,16,17)

HIDE SMILES / InChI

Molecular Formula	C15H21N3O2S
Molecular Weight	307.411
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf
Curator's Comment: description was created based on several sources, including http://pro-pharma.biz/?page_id=171

Fabomotizole (also known as Afobazole) is a selective non-benzodiazepine anxiolytic which was developed in Russia and launched in 2006. The drug is used for the treatment of wide range of diseases: generalized anxious disorders, neurasthenia, adaptation disorders, sleep disorders, for alleviation of withdrawal syndrome. According to the drug label (in Russian), its action is related to the interaction with sigma-1 receptors.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sigma opioid receptor 64 Target ID: CHEMBL287 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Agonist 2752		5.9 µM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Generalized anxiety disorder 32 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8583	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006
Neurasthenia 6 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8583	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006
Adjustment disorder 3 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8583	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006
Insomnia 111 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Primary	Approved 8583	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006
Withdrawal syndrome 3 Sources: http://www.afobazol.ru/files/afobazol_instrukciya.pdf	Palliative	Approved 8583	AFOBAZOLE Approved Use To treat generalized anxious disorders, neurasthenia, adaptation disorders at patients with dermatological, oncologic, somatic (bronchial asthma, syndrome of innervated intestinal tract, system lupus erythematosus, ischemic heart disease, arterial hypertension, arrhythmia) diseases. In combination of complex therapy of sleep disorders related to anxiety, neurocirculatory asthenia, premenstrual syndrome, for alleviation of state at smoking withdrawal symptoms. Launch Date 2006

Doses

Dose	Population	Adverse events
60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	Other AEs: Sleep disturbance, Anxiety... Other AEs: Sleep disturbance (9.7%) Anxiety (8.6%) Drowsiness (7.5%) Headache (5.4%) Irritability (3.2%) Hypertonia (2.7%) Hypotonia (1.6%) Dry mouth (1.6%) Muscle weakness (1.6%) Nausea (1.1%) Lumbar pain (0.5%) Tremor (0.5%) Disturbances of accommodation (0.5%) Frequent urination (0.5%) Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/

AEs

AE	Significance	Dose	Population
Disturbances of accommodation	0.5%	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/
Frequent urination	0.5%	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/
Lumbar pain	0.5%	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/
Tremor	0.5%	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/
Nausea	1.1%	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/
Dry mouth	1.6%	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/
Hypotonia	1.6%	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/
Muscle weakness	1.6%	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/
Hypertonia	2.7%	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/
Irritability	3.2%	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/
Headache	5.4%	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/
Drowsiness	7.5%	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/
Anxiety	8.6%	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/
Sleep disturbance	9.7%	60 mg 3 times / day multiple, oral Highest studied dose Dose: 60 mg, 3 times / day Route: oral Route: multiple Dose: 60 mg, 3 times / day Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FED Sources: https://www.rmj.ru/articles/psikhiatriya/Effektivnosty_i_perenosimosty_terapii_Afobazolom_rezulytaty_otkrytoy_mulyticentrovoy_naturalisticheskoy_programmy/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/9862937#section=Biological-Test-Results Page: 3.0	inconclusive [IC50 18.9991 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/9862937#section=Biological-Test-Results Page: 4.0	inconclusive [IC50 37.9083 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/9862937#section=Biological-Test-Results Page: 3.0	yes [IC50 10.684 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/9862937#section=Biological-Test-Results Page: 9 \| 10	no

PubMed

Title	Date	PubMed
[Comparative study of the interoceptive effects of afobazole and diazepam].	2010-10	21254504
Comparative analysis of tissue availability for afobazole and compound M-11.	2010-09	21246091
On the mechanism of antifibrillatory effect of afobazole.	2010-09	21246090
Effect of afobazole on genotoxic effects of tobacco smoke in the placenta and embryonic tissues of rats.	2010-09	21246089
[Anxiolytic afobazole action self-evaluated by patients with anxiety-asthenic disorders].	2010-09	21086645
Neuroprotective properties of afobazole in repeated hemorrhagic stroke modeling in aged rats.	2010-08	21113492
Effects of selective anxiolytic afobazole on active caspase-3.	2010-08	21113491
[Model study of afobazole distribution in pregnant and lactating female rats and infant rat pups].	2010-08	20919552
[Antiarrhythmic properties of afobazole and other 2-mercaptobensimidazole derivatives].	2010-05	20597362
[Cerebrovascular effects of afobazole under conditions of combined disorders of cerebral and coronary circulation].	2010-05	20597361
[Neurochemical study of effects of the new anxiolytic drugs afobazol and ladasten on the synthesis and metabolism of monoamines and their metabolites in the brain structures of Wistar rat on the model of monoamine synthesis blockade induced by aromatic amino acid decarboxylase inhibitor NSD-1015].	2010-03	20408420
[Afobazole effect on cerebral circulation under hemorrhagic stroke model conditions].	2010-01-26	20095394
[Effectiveness of combined application of ursosan and anxiolytic 2-mercaptobenzimidazole in early stage of cholelithiasis].	2010	20623958
[Afobasol efficacy in a model of vagotonic atrial fibrillation].	2010	20540357
[Afobasol antifibrillation activity in animals with the intact and denervated myocardium].	2010	20540356
[Effects of afobasol in the reperfusion arrhythmia model].	2010	20540355
Effect of afobazole on DNA damage in patients with systemic lupus erythematosus.	2009-10	20396750
Interaction of afobazole with sigma1-receptors.	2009-07	19902093
Effect of afobazole on mitochondrial monoamine oxidase A activity in vitro.	2009-07	19902087
[Antimutagenic and antiteratogenic properties of afobazole].	2009-04-02	19334511
[Specific effects of selective anxiolytic afobazole on the cardiovascular system].	2009-04-02	19334510
[Afobazole effect on heart rate variability in rats with different behaviors in the "open field" test].	2009-04-02	19334509
[Effects of afobazole on the stress protein HSP70 level in the brain tissue of rats with global transient ischemia].	2009-04-02	19334508
[Neuroprotective effects of afobazole in a hemorrhagic stroke model].	2009-04-02	19334507
[Afobazole influence on antinociceptive properties of morphine].	2009-04-02	19334506
[Antidepressant properties of afobazole in Porsolt and Nomura tests].	2009-04-02	19334505
[Afobazole decreases motor side effects induced by haloperidol].	2009-04-02	19334504
[Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons].	2009-04-02	19334503
[Neuroreceptor mechanisms of the afobazole effect].	2009-04-02	19334502
Gateways to clinical trials. December 2008.	2008-12	19271026
[Afobazole metabolism in rats].	2008-05-21	18488909
Excretion of afobazole and its metabolites with urine and feces in rats.	2008-04	19110588
Effect of afobazole on teratogenic activity of cyclophosphamide in rats.	2008-04	19110587
Neuroprotective effect of afobazole on rats with bilateral local photothrombosis of vessels in the prefrontal cortex.	2008-02	19023970
In vivo effects of afobazole (2-mercaptobenzimidazole derivative) on the 7,12-dimethylbenz [alpha]anthracene-induced oncogene and suppressor gene expression.	2008-01-24	18210756
[Administration of afobasol for correction of mental disorders in celiac disease patients].	2008	19105406
[Efficacy of aphobazole in the treatment of anxiety disorders in patients with chronic cerebro-vascular insufficiency].	2008	18800419
[Using of aphobazol in the treatment of adaptation disorder in the contract service men, dismissed from the armed forces].	2007-11	18306710
[Pharmacokinetics of afobazole in rats].	2007-05-26	17523455
Tissue availability of afobazole and its major metabolites in rats.	2007-05	18239776
[Psychopharmacotherapy of anxiety disorders in patients with cardio-vascular diseases: the use of aphobazole].	2007	18379478
[A comparative study of the effect of afobazole on brain monoamine systems in BALB/C and C57BL/6 mice].	2006-12-13	17153957
[Effect of afobazole on the accumulation of free radical oxidation products and the catalase activity in rats with cerebral ischemia].	2006-09-26	16995439
[Evidence for the neuroprotective properties of afobazole in experimental model of focal brain ischemia].	2006-09-26	16995428
[Effects of afobazole on the BDNF content in brain structures of inbred mice with different phenotypes of emotional stress reaction].	2006-08-02	16878488
Studies of long-term noopept and afobazol treatment in rats with learned helplessness neurosis.	2006-08	17369939
[Effect of afobazole on brain-ischemia-induced anxiety in rats].	2006-07-19	16845930
[Effect of afobazole on transmembrane ion currents in mollusk neurons].	2005-11-10	16277200
Neuroprotective effects of afobazol in experimental cerebral hemorrhage.	2005-11	16758618
Neuroprotective properties of afobazol in vitro.	2005-08	16282999

Patents

Sample Use Guides

In Vivo Use Guide

For adult persons and children it is recommended to use internally, after meal. Usually it is recommended to use 1 tablet (10 mg) trice per day. The maximum daily dose is 60 mg. The period of therapy is 2-4 weeks. According to doctor prescription it is possible to prolong the period up to 3 months.

Route of Administration: Oral

In Vitro Use Guide

Experiments on immortalized hippocampal cell culture of mice showed that afobazole increases the NGF level in a final concentration of 10(-8) M and the BDNF level in final concentrations from 10(-8) to 10(-5) M.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 09:37:02 GMT 2025` Edited by `admin` on `Wed Apr 02 09:37:02 GMT 2025`
Record UNII	0F8K1X115C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FABOMOTIZOLE

Official Name

English

CM-346

Preferred Name

English

AFOBAZOLE

Common Name

English

1H-BENZIMIDAZOLE, 5-ETHOXY-2-((2-(4-MORPHOLINYL)ETHYL)THIO)-

Systematic Name

English

APHOBAZOLE

Common Name

English

AFOBAZOL

Common Name

English

OBENOXAZINE

Common Name

English

Fabomotizole [WHO-DD]

Common Name

English

fabomotizole [INN]

Common Name

English

5-ETHOXY-2-((2-(MORPHOLIN-4-YL)ETHYL)SULFANYL)-1H-BENZIMIDAZOLE

Systematic Name

English

Classification Tree Code System Code

WHO-ATC

N05BX04